Aldoxorubicin is under clinical development by LadRx and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aldoxorubicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aldoxorubicin overview
Aldoxorubicin (INNO-206, DOXO-EMCH, doxorubicin-EMCH) is under development for the treatment of solid tumors including advanced, triple-negative breast cancer, metastatic pancreatic cancer, glioblastoma multiforme and non-small cell lung cancer, relapsed and refractory colorectal cancer. The drug candidate is administered as an intravenous infusion. The drug candidate targets DNA synthesis. Aldoxorubicin is a tumor-targeted doxorubicin conjugate. The drug candidate is a (6-Maleimidocaproyl) hydrazone of doxorubicin. It is based on conjugated tumor-targeted technology. INNO-206 is a chemically modified version of doxorubicin that incorporates an acid sensitive linker technology to improve targeting to the tumor.
It was also under the development for the treatment of advanced squamous cell carcinoma (SCC) as head and neck cancer, ovarian cancer, metastatic small cell lung cancer (SCLC), soft tissue sarcoma, kaposi sarcoma, metastatic pancreatic ductal adenocarcinoma, bone cancer including rhabdomyosarcoma, Ewing's sarcoma and mixed mesodermal sarcoma), chondrosarcoma or osteosarcoma of intermediate or high grade, gastrointestinal stromal tumors.
LadRx overview
LadRx formerly CytRx, is a biopharmaceutical company that focuses on the discovery and development of new therapeutics for the treatment of cancer and neurodegenerative diseases. LadRx’s product candidate, aldoxorubicin, is in the late stage of clinical development, and finds application in treating relapsed soft tissue melanoma, small-cell lung cancer, and other types of cancer with unmet medical needs. The company also has other pipeline products being developed through linker activated drug release technology platform. It has milestone and royalty agreements with Orphazyme A/S, Centurion and NantCell, Inc. (now ImmunityBio, Inc.), which could generate substantial revenue for the company. LadRx is headquartered in Los Angeles, California, the US.
For a complete picture of Aldoxorubicin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
